Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy

Abstract

Introduction: Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening disease, defined as idiopathic cardiomyopathy occurring towards the end of pregnancy or in the months following delivery, abortion or miscarriage. We aim to raise awareness of this condition and give an overview of current knowledge as well as an insight and comparison of clinical trials focusing on randomized controlled trials. Material and methods: Systematic literature searches were conducted using PubMed up to December 2021. Studies published involving clinical trials and interventions in women with PPCM after 1970 were selected. Results: Randomized controlled trials have shown that addition of Bromocriptine to standardized heart failure therapy improves outcome in terms of recovery of left ventricular ejection fraction (LVEF), symptoms and death. Bromocriptine 2.5 mg twice daily for two weeks followed by 2.5 mg once daily for six weeks had the best trend anAddition of Levosimendan to standardized heart failure therapy had no effect, whereas addition of Selenium had an improvement in heart failure symptoms but did not reduce risk in terms of unrecovered LVEF or death. One prospective study showed a potential usage of TNF-alfa inhibitors, but was never tried in a randomized clinical trial.d outcome. Conclusion: PPCM is a rare and potentially fatal disease. New insights in pathophysiology, genetics and clinical studies, particularly randomized controlled trials have shown that addition of Bromocriptine has a beneficial effect in terms of improved LVEF and death. However, some clinical studies have shown promising results using anti-inflammatory pharmacological agents with an improvement in LVEF. We suggest that targeting an anti-inflammatory route may prove beneficial in patients with PPCM. However, further research is highly warranted.